AustralieFrV1, PascalFrancis, Corpus, bibRecord, 001820

Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT2c antagonist, S32006

Identifieur interne : 001820 ( PascalFrancis/Corpus ); précédent : 001819; suivant : 001821

Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT2c antagonist, S32006

Auteurs : Trevor R. Norman ; Ingrid Cranston ; Jeremy A. Irons ; Cecilia Gabriel ; Anne Dekeyne ; Mark J. Millan ; Elisabeth Mocaer

Source :

European journal of pharmacology [ 0014-2999 ] ; 2012.

RBID : Francis:12-0020338

Descripteurs français

Pascal (Inist)
- Agomélatine, Locomotion, Hyperactivité, Animal, Rat, Etude comparative, Mélatonine, Antagoniste, Antidépresseur, Imipramine, Comportement en champ libre, Etat dépressif, Modèle, Psychotrope.

English descriptors

KwdEn :
- Agomelatine, Animal, Antagonist, Antidepressant agent, Comparative study, Depression, Hyperactivity, Imipramine, Locomotion, Melatonin, Models, Open field behavior, Psychotropic, Rat.

Abstract

The novel melatonergic agonist/5-HT_2C antagonist agomelatine displays robust antidepressant properties in humans and is active in pre-clinical models predictive of antidepressant effects. In this study, we investigated its potential influence on the locomotor hyperactivity displayed by olfactory bulbectomised rats, a putative measure of potential antidepressant activity. In addition, we compared the actions of agomelatine to those of melatonin and S32006, a selective antagonist at 5-HT_2C receptors. Vehicle, agomelatine (10 and 50 mg/kg), melatonin (10 and 50 mg/kg), S32006 (0.16 mg/kg to 10 mg/kg) and the prototypical tricyclic antidepressant, imipramine (10 mg/kg), were administered by intraperitoneal injection for 14 days to male, Sprague-Dawley sham-operated and bulbectomised rats. In agreement with previous studies, imipramine was active in the model and both the lower and higher doses of agomelatine also significantly and markedly reversed the bulbectomy-induced hyperactivity to a level comparable to that seen in sham operated animals, in which agomelatine exerted no effect. Similarly the 5-HT_2C antagonist, S32006, dose-dependently and significantly attenuated hyperactivity of bulbectomised animals, albeit with a maximal effect somewhat less marked than that of agomelatine. On the other hand, melatonin did not affect the locomotor behaviour of bulbectomised rats. The activity of agomelatine in the model is consistent with its known antidepressant properties in the clinic.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0014-2999`
A02	`01`			`@0 EJPHAZ`
A03		`1`		`@0 Eur. j. pharmacol.`
A05				`@2 674`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT_2c antagonist, S32006`
A11	`01`	`1`		`@1 NORMAN (Trevor R.)`
A11	`02`	`1`		`@1 CRANSTON (Ingrid)`
A11	`03`	`1`		`@1 IRONS (Jeremy A.)`
A11	`04`	`1`		`@1 GABRIEL (Cecilia)`
A11	`05`	`1`		`@1 DEKEYNE (Anne)`
A11	`06`	`1`		`@1 MILLAN (Mark J.)`
A11	`07`	`1`		`@1 MOCAER (Elisabeth)`
A14	`01`			`@1 Department of Psychiatry, University of Melbourne, Austin Hospital @2 Heidelberg, Victoria 3084 @3 AUS @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A14	`02`			`@1 IRIS @2 Courbevoie, Croissy-sur-Seine @3 FRA @Z 4 aut. @Z 7 aut.`
A14	`03`			`@1 IDR Servier @2 Croissy-sur-Seine @3 FRA @Z 5 aut. @Z 6 aut.`
A20				`@1 27-32`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13322 @5 354000507359100050`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.1/4`
A47	`01`	`1`		`@0 12-0020338`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 European journal of pharmacology`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 The novel melatonergic agonist/5-HT_2C antagonist agomelatine displays robust antidepressant properties in humans and is active in pre-clinical models predictive of antidepressant effects. In this study, we investigated its potential influence on the locomotor hyperactivity displayed by olfactory bulbectomised rats, a putative measure of potential antidepressant activity. In addition, we compared the actions of agomelatine to those of melatonin and S32006, a selective antagonist at 5-HT_2C receptors. Vehicle, agomelatine (10 and 50 mg/kg), melatonin (10 and 50 mg/kg), S32006 (0.16 mg/kg to 10 mg/kg) and the prototypical tricyclic antidepressant, imipramine (10 mg/kg), were administered by intraperitoneal injection for 14 days to male, Sprague-Dawley sham-operated and bulbectomised rats. In agreement with previous studies, imipramine was active in the model and both the lower and higher doses of agomelatine also significantly and markedly reversed the bulbectomy-induced hyperactivity to a level comparable to that seen in sham operated animals, in which agomelatine exerted no effect. Similarly the 5-HT_2C antagonist, S32006, dose-dependently and significantly attenuated hyperactivity of bulbectomised animals, albeit with a maximal effect somewhat less marked than that of agomelatine. On the other hand, melatonin did not affect the locomotor behaviour of bulbectomised rats. The activity of agomelatine in the model is consistent with its known antidepressant properties in the clinic.
C02	`01`	`X`		`@0 770D03G01 @1 IV`
C03	`01`	`X`	`FRE`	`@0 Agomélatine @2 NK @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Agomelatine @2 NK @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Agomelatina @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Locomotion @5 02`
C03	`02`	`X`	`ENG`	`@0 Locomotion @5 02`
C03	`02`	`X`	`SPA`	`@0 Locomoción @5 02`
C03	`03`	`X`	`FRE`	`@0 Hyperactivité @5 03`
C03	`03`	`X`	`ENG`	`@0 Hyperactivity @5 03`
C03	`03`	`X`	`SPA`	`@0 Hiperactividad @5 03`
C03	`04`	`X`	`FRE`	`@0 Animal @5 04`
C03	`04`	`X`	`ENG`	`@0 Animal @5 04`
C03	`04`	`X`	`SPA`	`@0 Animal @5 04`
C03	`05`	`X`	`FRE`	`@0 Rat @5 05`
C03	`05`	`X`	`ENG`	`@0 Rat @5 05`
C03	`05`	`X`	`SPA`	`@0 Rata @5 05`
C03	`06`	`X`	`FRE`	`@0 Etude comparative @5 06`
C03	`06`	`X`	`ENG`	`@0 Comparative study @5 06`
C03	`06`	`X`	`SPA`	`@0 Estudio comparativo @5 06`
C03	`07`	`X`	`FRE`	`@0 Mélatonine @5 07`
C03	`07`	`X`	`ENG`	`@0 Melatonin @5 07`
C03	`07`	`X`	`SPA`	`@0 Melatonina @5 07`
C03	`08`	`X`	`FRE`	`@0 Antagoniste @5 08`
C03	`08`	`X`	`ENG`	`@0 Antagonist @5 08`
C03	`08`	`X`	`SPA`	`@0 Antagonista @5 08`
C03	`09`	`X`	`FRE`	`@0 Antidépresseur @5 09`
C03	`09`	`X`	`ENG`	`@0 Antidepressant agent @5 09`
C03	`09`	`X`	`SPA`	`@0 Antidepresor @5 09`
C03	`10`	`X`	`FRE`	`@0 Imipramine @2 NK @2 FR @5 10`
C03	`10`	`X`	`ENG`	`@0 Imipramine @2 NK @2 FR @5 10`
C03	`10`	`X`	`SPA`	`@0 Imipramina @2 NK @2 FR @5 10`
C03	`11`	`X`	`FRE`	`@0 Comportement en champ libre @5 11`
C03	`11`	`X`	`ENG`	`@0 Open field behavior @5 11`
C03	`11`	`X`	`SPA`	`@0 Conducta en campo abierto @5 11`
C03	`12`	`X`	`FRE`	`@0 Etat dépressif @5 12`
C03	`12`	`X`	`ENG`	`@0 Depression @5 12`
C03	`12`	`X`	`SPA`	`@0 Estado depresivo @5 12`
C03	`13`	`X`	`FRE`	`@0 Modèle @5 13`
C03	`13`	`X`	`ENG`	`@0 Models @5 13`
C03	`13`	`X`	`SPA`	`@0 Modelo @5 13`
C03	`14`	`X`	`FRE`	`@0 Psychotrope @2 FX @5 26`
C03	`14`	`X`	`ENG`	`@0 Psychotropic @2 FX @5 26`
C03	`14`	`X`	`SPA`	`@0 Psicotropo @2 FX @5 26`
C07	`01`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`02`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`FRE`	`@0 Analogue @5 37`
C07	`04`	`X`	`ENG`	`@0 Analog @5 37`
C07	`04`	`X`	`SPA`	`@0 Análogo @5 37`
C07	`05`	`X`	`FRE`	`@0 Hormone épiphysaire @5 38`
C07	`05`	`X`	`ENG`	`@0 Pineal hormone @5 38`
C07	`05`	`X`	`SPA`	`@0 Hormona epifisaria @5 38`
C07	`06`	`X`	`FRE`	`@0 Amine tertiaire @5 39`
C07	`06`	`X`	`ENG`	`@0 Tertiary amine @5 39`
C07	`06`	`X`	`SPA`	`@0 Amina terciaria @5 39`
C07	`07`	`X`	`FRE`	`@0 Composé tricyclique @5 40`
C07	`07`	`X`	`ENG`	`@0 Tricyclic compound @5 40`
C07	`07`	`X`	`SPA`	`@0 Compuesto tricíclico @5 40`
C07	`08`	`X`	`FRE`	`@0 Inhibiteur recapture @5 41`
C07	`08`	`X`	`ENG`	`@0 Reuptake inhibitor @5 41`
C07	`08`	`X`	`SPA`	`@0 Inhibidor recaptura @5 41`
C07	`09`	`X`	`FRE`	`@0 Noradrénaline @2 NK @5 42`
C07	`09`	`X`	`ENG`	`@0 Norepinephrine @2 NK @5 42`
C07	`09`	`X`	`SPA`	`@0 Noradrenalina @2 NK @5 42`
C07	`10`	`X`	`FRE`	`@0 Sérotonine @2 NK @2 FR @5 43`
C07	`10`	`X`	`ENG`	`@0 Serotonin @2 NK @2 FR @5 43`
C07	`10`	`X`	`SPA`	`@0 Serotonina @2 NK @2 FR @5 43`
C07	`11`	`X`	`FRE`	`@0 Trouble de l'humeur @5 44`
C07	`11`	`X`	`ENG`	`@0 Mood disorder @5 44`
C07	`11`	`X`	`SPA`	`@0 Trastorno humor @5 44`
C07	`12`	`X`	`FRE`	`@0 Catécholamine @5 45`
C07	`12`	`X`	`ENG`	`@0 Catecholamine @5 45`
C07	`12`	`X`	`SPA`	`@0 Catecolamina @5 45`
C07	`13`	`X`	`FRE`	`@0 Neurotransmetteur @5 46`
C07	`13`	`X`	`ENG`	`@0 Neurotransmitter @5 46`
C07	`13`	`X`	`SPA`	`@0 Neurotransmisor @5 46`
C07	`14`	`X`	`FRE`	`@0 Dérivé de la dihydrodibenzazépine @4 INC @5 86`
N21				`@1 009`

Format Inist (serveur)

NO :	FRANCIS 12-0020338 INIST
ET :	Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT_2c antagonist, S32006
AU :	NORMAN (Trevor R.); CRANSTON (Ingrid); IRONS (Jeremy A.); GABRIEL (Cecilia); DEKEYNE (Anne); MILLAN (Mark J.); MOCAER (Elisabeth)
AF :	Department of Psychiatry, University of Melbourne, Austin Hospital/Heidelberg, Victoria 3084/Australie (1 aut., 2 aut., 3 aut.); IRIS/Courbevoie, Croissy-sur-Seine/France (4 aut., 7 aut.); IDR Servier/Croissy-sur-Seine/France (5 aut., 6 aut.)
DT :	Publication en série; Niveau analytique
SO :	European journal of pharmacology; ISSN 0014-2999; Coden EJPHAZ; Pays-Bas; Da. 2012; Vol. 674; No. 1; Pp. 27-32; Bibl. 1 p.1/4
LA :	Anglais
EA :	The novel melatonergic agonist/5-HT_2C antagonist agomelatine displays robust antidepressant properties in humans and is active in pre-clinical models predictive of antidepressant effects. In this study, we investigated its potential influence on the locomotor hyperactivity displayed by olfactory bulbectomised rats, a putative measure of potential antidepressant activity. In addition, we compared the actions of agomelatine to those of melatonin and S32006, a selective antagonist at 5-HT_2C receptors. Vehicle, agomelatine (10 and 50 mg/kg), melatonin (10 and 50 mg/kg), S32006 (0.16 mg/kg to 10 mg/kg) and the prototypical tricyclic antidepressant, imipramine (10 mg/kg), were administered by intraperitoneal injection for 14 days to male, Sprague-Dawley sham-operated and bulbectomised rats. In agreement with previous studies, imipramine was active in the model and both the lower and higher doses of agomelatine also significantly and markedly reversed the bulbectomy-induced hyperactivity to a level comparable to that seen in sham operated animals, in which agomelatine exerted no effect. Similarly the 5-HT_2C antagonist, S32006, dose-dependently and significantly attenuated hyperactivity of bulbectomised animals, albeit with a maximal effect somewhat less marked than that of agomelatine. On the other hand, melatonin did not affect the locomotor behaviour of bulbectomised rats. The activity of agomelatine in the model is consistent with its known antidepressant properties in the clinic.
CC :	770D03G01
FD :	Agomélatine; Locomotion; Hyperactivité; Animal; Rat; Etude comparative; Mélatonine; Antagoniste; Antidépresseur; Imipramine; Comportement en champ libre; Etat dépressif; Modèle; Psychotrope
FG :	Rodentia; Mammalia; Vertebrata; Analogue; Hormone épiphysaire; Amine tertiaire; Composé tricyclique; Inhibiteur recapture; Noradrénaline; Sérotonine; Trouble de l'humeur; Catécholamine; Neurotransmetteur; Dérivé de la dihydrodibenzazépine
ED :	Agomelatine; Locomotion; Hyperactivity; Animal; Rat; Comparative study; Melatonin; Antagonist; Antidepressant agent; Imipramine; Open field behavior; Depression; Models; Psychotropic
EG :	Rodentia; Mammalia; Vertebrata; Analog; Pineal hormone; Tertiary amine; Tricyclic compound; Reuptake inhibitor; Norepinephrine; Serotonin; Mood disorder; Catecholamine; Neurotransmitter
SD :	Agomelatina; Locomoción; Hiperactividad; Animal; Rata; Estudio comparativo; Melatonina; Antagonista; Antidepresor; Imipramina; Conducta en campo abierto; Estado depresivo; Modelo; Psicotropo
LO :	INIST-13322.354000507359100050
ID :	12-0020338

Links to Exploration step

Francis:12-0020338

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT<sub>2c</sub>
 antagonist, S32006</title>
<author><name sortKey="Norman, Trevor R" sort="Norman, Trevor R" uniqKey="Norman T" first="Trevor R." last="Norman">Trevor R. Norman</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Melbourne, Austin Hospital</s1>
<s2>Heidelberg, Victoria 3084</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cranston, Ingrid" sort="Cranston, Ingrid" uniqKey="Cranston I" first="Ingrid" last="Cranston">Ingrid Cranston</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Melbourne, Austin Hospital</s1>
<s2>Heidelberg, Victoria 3084</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Irons, Jeremy A" sort="Irons, Jeremy A" uniqKey="Irons J" first="Jeremy A." last="Irons">Jeremy A. Irons</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Melbourne, Austin Hospital</s1>
<s2>Heidelberg, Victoria 3084</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gabriel, Cecilia" sort="Gabriel, Cecilia" uniqKey="Gabriel C" first="Cecilia" last="Gabriel">Cecilia Gabriel</name>
<affiliation><inist:fA14 i1="02"><s1>IRIS</s1>
<s2>Courbevoie, Croissy-sur-Seine</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dekeyne, Anne" sort="Dekeyne, Anne" uniqKey="Dekeyne A" first="Anne" last="Dekeyne">Anne Dekeyne</name>
<affiliation><inist:fA14 i1="03"><s1>IDR Servier</s1>
<s2>Croissy-sur-Seine</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Millan, Mark J" sort="Millan, Mark J" uniqKey="Millan M" first="Mark J." last="Millan">Mark J. Millan</name>
<affiliation><inist:fA14 i1="03"><s1>IDR Servier</s1>
<s2>Croissy-sur-Seine</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mocaer, Elisabeth" sort="Mocaer, Elisabeth" uniqKey="Mocaer E" first="Elisabeth" last="Mocaer">Elisabeth Mocaer</name>
<affiliation><inist:fA14 i1="02"><s1>IRIS</s1>
<s2>Courbevoie, Croissy-sur-Seine</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0020338</idno>
<date when="2012">2012</date>
<idno type="stanalyst">FRANCIS 12-0020338 INIST</idno>
<idno type="RBID">Francis:12-0020338</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001820</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT<sub>2c</sub>
 antagonist, S32006</title>
<author><name sortKey="Norman, Trevor R" sort="Norman, Trevor R" uniqKey="Norman T" first="Trevor R." last="Norman">Trevor R. Norman</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Melbourne, Austin Hospital</s1>
<s2>Heidelberg, Victoria 3084</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cranston, Ingrid" sort="Cranston, Ingrid" uniqKey="Cranston I" first="Ingrid" last="Cranston">Ingrid Cranston</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Melbourne, Austin Hospital</s1>
<s2>Heidelberg, Victoria 3084</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Irons, Jeremy A" sort="Irons, Jeremy A" uniqKey="Irons J" first="Jeremy A." last="Irons">Jeremy A. Irons</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Melbourne, Austin Hospital</s1>
<s2>Heidelberg, Victoria 3084</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gabriel, Cecilia" sort="Gabriel, Cecilia" uniqKey="Gabriel C" first="Cecilia" last="Gabriel">Cecilia Gabriel</name>
<affiliation><inist:fA14 i1="02"><s1>IRIS</s1>
<s2>Courbevoie, Croissy-sur-Seine</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dekeyne, Anne" sort="Dekeyne, Anne" uniqKey="Dekeyne A" first="Anne" last="Dekeyne">Anne Dekeyne</name>
<affiliation><inist:fA14 i1="03"><s1>IDR Servier</s1>
<s2>Croissy-sur-Seine</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Millan, Mark J" sort="Millan, Mark J" uniqKey="Millan M" first="Mark J." last="Millan">Mark J. Millan</name>
<affiliation><inist:fA14 i1="03"><s1>IDR Servier</s1>
<s2>Croissy-sur-Seine</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mocaer, Elisabeth" sort="Mocaer, Elisabeth" uniqKey="Mocaer E" first="Elisabeth" last="Mocaer">Elisabeth Mocaer</name>
<affiliation><inist:fA14 i1="02"><s1>IRIS</s1>
<s2>Courbevoie, Croissy-sur-Seine</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European journal of pharmacology</title>
<title level="j" type="abbreviated">Eur. j. pharmacol.</title>
<idno type="ISSN">0014-2999</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European journal of pharmacology</title>
<title level="j" type="abbreviated">Eur. j. pharmacol.</title>
<idno type="ISSN">0014-2999</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agomelatine</term>
<term>Animal</term>
<term>Antagonist</term>
<term>Antidepressant agent</term>
<term>Comparative study</term>
<term>Depression</term>
<term>Hyperactivity</term>
<term>Imipramine</term>
<term>Locomotion</term>
<term>Melatonin</term>
<term>Models</term>
<term>Open field behavior</term>
<term>Psychotropic</term>
<term>Rat</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Agomélatine</term>
<term>Locomotion</term>
<term>Hyperactivité</term>
<term>Animal</term>
<term>Rat</term>
<term>Etude comparative</term>
<term>Mélatonine</term>
<term>Antagoniste</term>
<term>Antidépresseur</term>
<term>Imipramine</term>
<term>Comportement en champ libre</term>
<term>Etat dépressif</term>
<term>Modèle</term>
<term>Psychotrope</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The novel melatonergic agonist/5-HT<sub>2C</sub>
 antagonist agomelatine displays robust antidepressant properties in humans and is active in pre-clinical models predictive of antidepressant effects. In this study, we investigated its potential influence on the locomotor hyperactivity displayed by olfactory bulbectomised rats, a putative measure of potential antidepressant activity. In addition, we compared the actions of agomelatine to those of melatonin and S32006, a selective antagonist at 5-HT<sub>2C</sub>
 receptors. Vehicle, agomelatine (10 and 50 mg/kg), melatonin (10 and 50 mg/kg), S32006 (0.16 mg/kg to 10 mg/kg) and the prototypical tricyclic antidepressant, imipramine (10 mg/kg), were administered by intraperitoneal injection for 14 days to male, Sprague-Dawley sham-operated and bulbectomised rats. In agreement with previous studies, imipramine was active in the model and both the lower and higher doses of agomelatine also significantly and markedly reversed the bulbectomy-induced hyperactivity to a level comparable to that seen in sham operated animals, in which agomelatine exerted no effect. Similarly the 5-HT<sub>2C</sub>
 antagonist, S32006, dose-dependently and significantly attenuated hyperactivity of bulbectomised animals, albeit with a maximal effect somewhat less marked than that of agomelatine. On the other hand, melatonin did not affect the locomotor behaviour of bulbectomised rats. The activity of agomelatine in the model is consistent with its known antidepressant properties in the clinic.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0014-2999</s0>
</fA01>
<fA02 i1="01"><s0>EJPHAZ</s0>
</fA02>
<fA03 i2="1"><s0>Eur. j. pharmacol.</s0>
</fA03>
<fA05><s2>674</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT<sub>2c</sub>
 antagonist, S32006</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>NORMAN (Trevor R.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CRANSTON (Ingrid)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>IRONS (Jeremy A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GABRIEL (Cecilia)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DEKEYNE (Anne)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MILLAN (Mark J.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MOCAER (Elisabeth)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Psychiatry, University of Melbourne, Austin Hospital</s1>
<s2>Heidelberg, Victoria 3084</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>IRIS</s1>
<s2>Courbevoie, Croissy-sur-Seine</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>IDR Servier</s1>
<s2>Croissy-sur-Seine</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>27-32</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13322</s2>
<s5>354000507359100050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0020338</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>European journal of pharmacology</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The novel melatonergic agonist/5-HT<sub>2C</sub>
 antagonist agomelatine displays robust antidepressant properties in humans and is active in pre-clinical models predictive of antidepressant effects. In this study, we investigated its potential influence on the locomotor hyperactivity displayed by olfactory bulbectomised rats, a putative measure of potential antidepressant activity. In addition, we compared the actions of agomelatine to those of melatonin and S32006, a selective antagonist at 5-HT<sub>2C</sub>
 receptors. Vehicle, agomelatine (10 and 50 mg/kg), melatonin (10 and 50 mg/kg), S32006 (0.16 mg/kg to 10 mg/kg) and the prototypical tricyclic antidepressant, imipramine (10 mg/kg), were administered by intraperitoneal injection for 14 days to male, Sprague-Dawley sham-operated and bulbectomised rats. In agreement with previous studies, imipramine was active in the model and both the lower and higher doses of agomelatine also significantly and markedly reversed the bulbectomy-induced hyperactivity to a level comparable to that seen in sham operated animals, in which agomelatine exerted no effect. Similarly the 5-HT<sub>2C</sub>
 antagonist, S32006, dose-dependently and significantly attenuated hyperactivity of bulbectomised animals, albeit with a maximal effect somewhat less marked than that of agomelatine. On the other hand, melatonin did not affect the locomotor behaviour of bulbectomised rats. The activity of agomelatine in the model is consistent with its known antidepressant properties in the clinic.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>770D03G01</s0>
<s1>IV</s1>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Agomélatine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Agomelatine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Agomelatina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Locomotion</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Locomotion</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Locomoción</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Hyperactivité</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Hyperactivity</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hiperactividad</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Animal</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Animal</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Animal</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Rat</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Rat</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Rata</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Mélatonine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Melatonin</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Melatonina</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Antidépresseur</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Antidepressant agent</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Antidepresor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Imipramine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Imipramine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Imipramina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Comportement en champ libre</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Open field behavior</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Conducta en campo abierto</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Depression</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Modèle</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Models</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Modelo</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Psychotrope</s0>
<s2>FX</s2>
<s5>26</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Psychotropic</s0>
<s2>FX</s2>
<s5>26</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Psicotropo</s0>
<s2>FX</s2>
<s5>26</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Analogue</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Analog</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Análogo</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Hormone épiphysaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Pineal hormone</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Hormona epifisaria</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Amine tertiaire</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Tertiary amine</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Amina terciaria</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Composé tricyclique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Tricyclic compound</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Compuesto tricíclico</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Inhibiteur recapture</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Reuptake inhibitor</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Inhibidor recaptura</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Noradrénaline</s0>
<s2>NK</s2>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Norepinephrine</s0>
<s2>NK</s2>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Noradrenalina</s0>
<s2>NK</s2>
<s5>42</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Sérotonine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Serotonin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Serotonina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>43</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Trouble de l'humeur</s0>
<s5>44</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>44</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>44</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>45</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>45</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>45</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>46</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>46</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>46</s5>
</fC07>
<fC07 i1="14" i2="X" l="FRE"><s0>Dérivé de la dihydrodibenzazépine</s0>
<s4>INC</s4>
<s5>86</s5>
</fC07>
<fN21><s1>009</s1>
</fN21>
</pA>
</standard>
<server><NO>FRANCIS 12-0020338 INIST</NO>
<ET>Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT<sub>2c</sub>
 antagonist, S32006</ET>
<AU>NORMAN (Trevor R.); CRANSTON (Ingrid); IRONS (Jeremy A.); GABRIEL (Cecilia); DEKEYNE (Anne); MILLAN (Mark J.); MOCAER (Elisabeth)</AU>
<AF>Department of Psychiatry, University of Melbourne, Austin Hospital/Heidelberg, Victoria 3084/Australie (1 aut., 2 aut., 3 aut.); IRIS/Courbevoie, Croissy-sur-Seine/France (4 aut., 7 aut.); IDR Servier/Croissy-sur-Seine/France (5 aut., 6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>European journal of pharmacology; ISSN 0014-2999; Coden EJPHAZ; Pays-Bas; Da. 2012; Vol. 674; No. 1; Pp. 27-32; Bibl. 1 p.1/4</SO>
<LA>Anglais</LA>
<EA>The novel melatonergic agonist/5-HT<sub>2C</sub>
 antagonist agomelatine displays robust antidepressant properties in humans and is active in pre-clinical models predictive of antidepressant effects. In this study, we investigated its potential influence on the locomotor hyperactivity displayed by olfactory bulbectomised rats, a putative measure of potential antidepressant activity. In addition, we compared the actions of agomelatine to those of melatonin and S32006, a selective antagonist at 5-HT<sub>2C</sub>
 receptors. Vehicle, agomelatine (10 and 50 mg/kg), melatonin (10 and 50 mg/kg), S32006 (0.16 mg/kg to 10 mg/kg) and the prototypical tricyclic antidepressant, imipramine (10 mg/kg), were administered by intraperitoneal injection for 14 days to male, Sprague-Dawley sham-operated and bulbectomised rats. In agreement with previous studies, imipramine was active in the model and both the lower and higher doses of agomelatine also significantly and markedly reversed the bulbectomy-induced hyperactivity to a level comparable to that seen in sham operated animals, in which agomelatine exerted no effect. Similarly the 5-HT<sub>2C</sub>
 antagonist, S32006, dose-dependently and significantly attenuated hyperactivity of bulbectomised animals, albeit with a maximal effect somewhat less marked than that of agomelatine. On the other hand, melatonin did not affect the locomotor behaviour of bulbectomised rats. The activity of agomelatine in the model is consistent with its known antidepressant properties in the clinic.</EA>
<CC>770D03G01</CC>
<FD>Agomélatine; Locomotion; Hyperactivité; Animal; Rat; Etude comparative; Mélatonine; Antagoniste; Antidépresseur; Imipramine; Comportement en champ libre; Etat dépressif; Modèle; Psychotrope</FD>
<FG>Rodentia; Mammalia; Vertebrata; Analogue; Hormone épiphysaire; Amine tertiaire; Composé tricyclique; Inhibiteur recapture; Noradrénaline; Sérotonine; Trouble de l'humeur; Catécholamine; Neurotransmetteur; Dérivé de la dihydrodibenzazépine</FG>
<ED>Agomelatine; Locomotion; Hyperactivity; Animal; Rat; Comparative study; Melatonin; Antagonist; Antidepressant agent; Imipramine; Open field behavior; Depression; Models; Psychotropic</ED>
<EG>Rodentia; Mammalia; Vertebrata; Analog; Pineal hormone; Tertiary amine; Tricyclic compound; Reuptake inhibitor; Norepinephrine; Serotonin; Mood disorder; Catecholamine; Neurotransmitter</EG>
<SD>Agomelatina; Locomoción; Hiperactividad; Animal; Rata; Estudio comparativo; Melatonina; Antagonista; Antidepresor; Imipramina; Conducta en campo abierto; Estado depresivo; Modelo; Psicotropo</SD>
<LO>INIST-13322.354000507359100050</LO>
<ID>12-0020338</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001820 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001820 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Francis:12-0020338
   |texte=   Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT2c antagonist, S32006
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT2c antagonist, S32006

Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT2c antagonist, S32006

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri